Pharmacological Management of Obsessive-Compulsive Disorder: A Review for Clinicians

REFERENCES

• Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):2–72.
   Google Scholar
• Greist JH. The comparative effectiveness of treatments for obsessive-compulsive disorder. Bull Menninger Clin 1998; 62(4, suppl A): A65–81.
   Google Scholar
• Marks I. Behaviour therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry 1997;42:1021–7.
   PubMed Web of Science ®Google Scholar
• Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145:1521–5.
   PubMed Web of Science ®Google Scholar
• Hohagen F, Winkelmann G, Rasche-Räuchle H, Hand I, König A, Münchau N, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and pla- cebo: results of a multicentre study. Br J Psychiatry 1998; 173(suppl 35):71–8.
   Google Scholar
• Van Balkom AJ, De Haan E, Van Oppen P, Spinhoven P, Hoog- duin KA, Van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998;186:492–9.
   Google Scholar
• O’Connor K, Todorov C, Robillard S, Borgeat F, Brault M. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psy- chiatry 1999;44:64–71.
   Google Scholar
• Joel SW. Twenty month study of iproniazid therapy. Dis Nerv Syst 1959;20:521–4.
   Google Scholar
• DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatr Ann 1989; 19:97–101.
   Web of Science ®Google Scholar
• Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Dominguez RA, Koran LM, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559–67.
   PubMed Web of Science ®Google Scholar
• Wheadon DE, Bushnell W, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Presented at the 32nd annual meeting of the American College of Neuropsychopharmacology, Honolulu, December 1993.
   Google Scholar
• Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multi- centre, double-blind, placebo-controlled trial. Int Clin Psy- chopharmacol 1996;11:21–9.
   PubMed Web of Science ®Google Scholar
• Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, et al. Double-blind parallel comparison of three dosages of ser- traline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289–95.
   PubMed Web of Science ®Google Scholar
• Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, parox- etine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997; 17:267–71.
   PubMed Web of Science ®Google Scholar
• Snyder S. Amitriptyline therapy of obsessive-compulsive neu- rosis. J Clin Psychiatry 1980;41:286–9.
   PubMed Web of Science ®Google Scholar
• Ananth J, Solyom L, Solyom C, Sookman D. Doxepin in the treatment of obsessive compulsive neurosis. Psychosomatics 1975;16:185–7.
   PubMed Web of Science ®Google Scholar
• Leonard HL, Swedo SE, Rapoport JL, Koby E, Lenane MC, Cheslow DL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adoles- cents: a double-blind crossover comparison. Arch Gen Psychia- try 1989;46:1088–92.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47:577–85.
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, Ninan B, Black DW, Stahl S, Greist JH, Lydi- ard B, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and ma- jor depressive disorders. Arch Gen Psychiatry 2000;57:76–82.
   Google Scholar
• Delgado PL, Moreno FA. Different roles for serotonin in anti- obsessional drug action and the pathophysiology of obsessive- compulsive disorder. Br J Psychiatry 1998;173(suppl 35):21–5.
   Google Scholar
• Greist JH, Jefferson JW. Pharmacotherapy for obsessive- compulsive disorder. Br J Psychiatry 1998;173(suppl 35):64–70.
   Google Scholar
• Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive- compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247–54.
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treat- ment of obsessive-compulsive disorder. Am J Psychiatry 1999; 156:1409–16.
   PubMed Web of Science ®Google Scholar
• Winsberg ME, Cassic KS, Koran LM. Hoarding in obsessive- compulsive disorder: a report of 20 cases. J Clin Psychiatry 1999;60:591–7.
   Google Scholar
• Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Assessment and treatment of other disorders. In: Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993:449–90.
   Google Scholar
• Van Balkom AJLM, Van Oppen P, Vermeulen AWA, Van Dyck R, Nauta MCE, Vorst HCM. A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antidepres- sants, behavior and cognitive therapy. Clin Psychol Rev 1994;14:359–81.
   Google Scholar
• Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psy- chiatry 1995;52:53–60.
   PubMed Web of Science ®Google Scholar
• Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta- analytic review. Br J Psychiatry 1995;166:424–43.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Spadaccini E, Hollander E. Meta-analysis of phar- macotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:11–8.
   PubMed Web of Science ®Google Scholar
• Abramowitz JS. Effectiveness of psychological and pharmaco- logical treatments for obsessive-compulsive disorder: a quanti- tative review. J Consult Clin Psychol 1997;65:44–52.
   PubMed Web of Science ®Google Scholar
• Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology 1998;136:205–16.
   PubMed Web of Science ®Google Scholar
• Fineberg N. Refining treatment approaches in obsessive- compulsive disorder. Int Clin Psychopharmacol 1996;11(suppl 5):13–22.
   Google Scholar
• Rasmussen SA. The meta-analytic saga of serotonin reuptake inhibitors in an obsessional world. CNS Spectr 1996;1:2–9.
   Google Scholar
• Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tol- liver TJ, et al. Controlled comparisons of clomipramine and flu- oxetine in the treatment of obsessive-compulsive disorder: be- havioral and biological results. Arch Gen Psychiatry 1990; 47:926–32.
   Google Scholar
• López-Ibor JJ Jr, Saiz J, Cottraux J, Note I, Viñas R, Bourgeois M, et al. Double-blind comparison of fluoxetine versus clo- mipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996;6:111–8.
   Google Scholar
• Todorov C, Brassard M, Fontaine R, Vezina M, Elie R. Fluoxe- tine versus clomipramine in obsessive-compulsive disorder. Presented at the 10th World Congress of Psychiatry, Madrid, August 1996.
   Google Scholar
• Smeraldi E, Erzegovesi S, Bianchi Y, Pasquali L, Gocchi S, Ronchi P. Fluvoxamine vs clomipramine treatment in obses- sive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 1992;8:63–5.
   Google Scholar
• Freeman CPL, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301–5.
   PubMed Web of Science ®Google Scholar
• Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hol- lander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121–9.
   Google Scholar
• Bisserbe JC, Lane RM, Flament MF. A double-blind compari- son of sertraline and clomipramine in outpatients with obses- sive-compulsive disorder. Eur Psychiatry 1997;12:82–93.
   PubMed Web of Science ®Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treat- ment of obsessive-compulsive disorder. Br J Psychiatry 1996; 169:468–74.
   PubMed Web of Science ®Google Scholar
• Cox BJ, Swinson RP, Morrison B, Lee PS. Clomipramine, fluox- etine, and behavior therapy in the treatment of obsessive- compulsive disorder: a meta-analysis. J Behav Ther Exp Psy- chiatry 1993;24:149–53.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55:406–13.
   PubMed Web of Science ®Google Scholar
• Lane R, Baldwin D. Selective serotonin inhibitor reuptake– induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208–21.
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London, En- gland: Pharmaceutical Press, March 2000.
   Google Scholar
• Koran LM. Obsessive-compulsive and related disorders in adults: a comprehensive clinical guide. Cambridge, England: Cambridge University Press, 1999.
   Google Scholar
• Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997;58(suppl 7):11–5.
   Google Scholar
• Taylor D, McConnell H, McConnell D, Kerwin R, eds. The South London and Maudsley NHS Trust 2001 prescribing guidelines. 6th ed. London, England: Dunitz, 2000.
   Google Scholar
• Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010–5.
   PubMed Web of Science ®Google Scholar
• Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996;53:304–8.
   Google Scholar
• Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first- trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–8.
   PubMed Web of Science ®Google Scholar
• Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609–10.
   PubMed Web of Science ®Google Scholar
• Edwards JG, Inman WHW, Wilton L, Pearce GL. Prescription event monitoring of 10,401 patients treated with fluvoxamine. Br J Psychiatry 1994;164:387–95.
   Google Scholar
• Bromiker R, Kaplan M. Apparent intrauterine fetal with- drawal from clomipramine hydrochloride [Letter]. JAMA 1994;272:1722–3.
   PubMed Web of Science ®Google Scholar
• Ostergaard GZ, Pedersen SE. Neonatal effects of maternal clomipramine treatment. Pediatrics 1982;69:233–4.
   PubMed Web of Science ®Google Scholar
• Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 1982;284:1837–8.
   PubMed Web of Science ®Google Scholar
• Goldberg HL, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994;24:129–47.
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258–62.
   PubMed Web of Science ®Google Scholar
• Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA. DSM-IV field trial: obsessive-compulsive dis- order. Am J Psychiatry 1995;152:90–6.
   PubMed Web of Science ®Google Scholar
• O’Dwyer AM, Marks I. Obsessive-compulsive disorder and delusions revisited. Br J Psychiatry 2000;176:281–4.
   PubMed Web of Science ®Google Scholar
• Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 1997;154:271–3.
   PubMed Web of Science ®Google Scholar
• Porto M, Bermanzohn EC, Pollack S. A profile of obsessive compulsive symptoms in schizophrenia. CNS Spectr 1997; 2:21–5.
   Google Scholar
• Sasson Y, Bermanzohn PC, Zohar J. Treatment of obsessive compulsive syndromes in schizophrenia. CNS Spectr 1997; 2:34–6.
   Google Scholar
• Panagiotis B, Maria G, Aris L. Development of obsessive and depressive symptoms during risperidone treatment [Letter]. Br J Psychiatry 1999;174:559.
   Google Scholar
• Allen L, Tejera C. Treatment of clozapine-induced obsessive- compulsive symptoms with sertraline [Letter]. Am J Psychia- try 1994;151:1096–7.
   PubMed Web of Science ®Google Scholar
• Baker RW, Ames D, Umbricht DSG, Chengappa KN, Schooler NR. Obsessive-compulsive symptoms in schizophrenia: a com- parison of olanzapine and placebo. Psychopharmacol Bull 1996;32:89–93.
   PubMedGoogle Scholar
• McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, et al. Neuroleptic addition in fluvoxamine- refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147:652–4.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo- controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302–8.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addi- tion in serotonin reuptake inhibitor–refractory obsessive- compulsive disorder. Arch Gen Psychiatry 2000;57:794–801.
   PubMed Web of Science ®Google Scholar
• Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive behav- ioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999;60:584–90.
   PubMed Web of Science ®Google Scholar
• Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clon- azepam, and clonidine treatment of obsessive-compulsive dis- order. J Clin Psychopharmacol 1992;12:420–30.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, White K. Clonazepam in the treatment of obsessive compulsive disorder associated with panic disorder in one pa- tient. J Clin Psychiatry 1989;50:265–6.
   PubMedGoogle Scholar
• Pigott TA, L’Heureux F, Rubenstein CS, Hill JL, Murphy DL. A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. Presented at the 145th Annual Meeting of the American Psychiatric Associa- tion, Washington, DC, May 1992.
   Google Scholar
• Pigott TA, L’Heureux F, Hill JL, Bihari K, Bernstein SE, Mur- phy DL. A double-blind study of adjuvant buspirone hydro- chloride in clomipramine-treated patients with obsessive- compulsive disorder. J Clin Psychopharmacol 1992;12:11–8.
   Google Scholar
• Jenike MA, Baer L, Buttolph L. Buspirone augmentation of flu- oxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991;52:13–4.
   PubMed Web of Science ®Google Scholar
• Grady TA, Pigott TA, L’Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disor- der. Am J Psychiatry 1993;150:819–21.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, et al. Limited therapeutic effect of the addition of buspirone in fluvoxamine-refractory obsessive- compulsive disorder. Am J Psychiatry 1993;150:647–9.
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R. Sequential administration of augmenta- tion strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 1996;11:37–44.
   Google Scholar
• Pigott TA, Pato MT, L’Heureux F, Hill JL, Grover GN, Bern- stein SE, et al. A controlled comparison of adjuvant lithium car- bonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:242–8.
   Google Scholar
• McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine- refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175–84.
   PubMed Web of Science ®Google Scholar
• McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997;58(suppl 12):11–7.
   Google Scholar
• Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive- compulsive and related disorders. J Clin Psychiatry 1997;58:119–22.
   PubMed Web of Science ®Google Scholar
• Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Thera- peutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder. Psychopharmacol Bull 1996; 32:677–82.
   PubMedGoogle Scholar
• Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmen- tation of fluvoxamine-refractory obsessive-compulsive disor- der (OCD): a 12-week open trial. Psychiatry Res 2000;96:91–8.
   PubMed Web of Science ®Google Scholar
• Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanza- pine addition in obsessive-compulsive disorder refractory to se- lective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524–7.
   PubMed Web of Science ®Google Scholar
• McDougle CT, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, et al. Lack of efficacy of clozapine monotherapy in re- fractory obsessive disorder. Am J Psychiatry 1995;152:1812–4.
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psy- chiatry 1999;14:101–6.
   Google Scholar
• Seedat S, Stein DJ. Inositol augmentation of serotonin reup- take inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol 1999;14:353–6.
   PubMed Web of Science ®Google Scholar
• Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219–21.
   PubMed Web of Science ®Google Scholar
• Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Re- bound psychiatric and physical symptoms after gabapentin discontinuation [Letter]. J Clin Psychiatry 1998;59:131.
   PubMed Web of Science ®Google Scholar
• Hollander E, DeCaria CM, Schneier FR, Schneier HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of sero- tonin reuptake blockade antiobsessional treatment. J Clin Psy- chiatry 1990;51:119–23.
   Google Scholar
• Judd FK, Chua P, Lynch C, Norman T. Fenfluramine augmen- tation of clomipramine treatment of obsessive compulsive dis- order. Aust NZ J Psychiatry 1991;25:412–4.
   PubMed Web of Science ®Google Scholar
• Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13:219–24.
   PubMed Web of Science ®Google Scholar
• Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 1996;40:547–9.
   PubMed Web of Science ®Google Scholar
• Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990;13:322–8.
   PubMedGoogle Scholar
• Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psy- chiatry 1997;154:1293–5.
   PubMed Web of Science ®Google Scholar
• Altemus M, Greenberg BD, Keuler D, Jacobson KR, Murphy DL. An open trial of flutamide in the treatment of obsessive- compulsive disorder. J Clin Psychiatry 1999;60:442–5.
   PubMed Web of Science ®Google Scholar
• Calvocoressi L, McDougle CI, Wasylink S, Goodman WK, Tru- fan SJ, Price LH. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry 1993;44:1150–4.
   Google Scholar
• Vallejo J, Olivares J, Marcos T, Bulbena A, Menchón JM. Clomipramine versus phenelzine in obsessive-compulsive dis- order: a controlled clinical trial. Br J Psychiatry 1992;161:665–70.
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261–4.
   PubMed Web of Science ®Google Scholar
• Rauch SL, O’Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases [Letter]. J Clin Psychopharmacol 1996;16:81–4.
   PubMed Web of Science ®Google Scholar
• Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine [Letter]. Am J Psychiatry 1996;153:576–7.
   PubMed Web of Science ®Google Scholar
• Ananth J, Burgoyne K, Smith M, Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder [Letter]. Am J Psy- chiatry 1995;152:1832.
   PubMed Web of Science ®Google Scholar
• Warneke LB. The use of intravenous chlorimipramine in the treatment of obsessive compulsive disorder. Can J Psychiatry 1984;29:135–41.
   Google Scholar
• Warneke LB. Intravenous chlorimipramine in the treatment of obsessional disorder in adolescence: case report. J Clin Psychi- atry 1985;46:100–3.
   Google Scholar
• Warneke L. Intravenous clomipramine therapy in obsessive- compulsive disorder. Can J Psychiatry 1989;34:853–9.
   Google Scholar
• Fallon BA, Campeas R, Schneier FR, Hollander E, Feerick J, Hatterer J, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive dis- order. J Neuropsychiatry Clin Neurosci 1992;4:70–5.
   Google Scholar
• Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, et al. Intravenous clomipramine for obsessive- compulsive disorder refractory to oral clomipramine: a placebo- controlled study. Arch Gen Psychiatry 1998;55:918–24.
   PubMed Web of Science ®Google Scholar
• Rabheru K, Persad E. A review of continuation and mainte- nance electroconvulsive therapy. Can J Psychiatry 1997;42:476–84.
   PubMed Web of Science ®Google Scholar
• Maletzky B, McFarland B, Burt A. Refractory obsessive com- pulsive disorder and ETC. Convuls Ther 1994;10:34–42.
   PubMedGoogle Scholar
• Jenike MA, Rauch SL, Baer L, Rasmussen SA. Neurosurgical treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-compulsive disorders: practical management. 3rd ed. London, England: Mosby, 1998: 592–610.
   Google Scholar
• Mindus P, Jenike MA. Neurosurgical treatment of malignant obsessive compulsive disorder. Psychiatr Clin North Am 1992; 15:921–38.
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Ballantine HT, Martuza RL, Tynes S, Giri- unas I, et al. Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 patients. Arch Gen Psy- chiatry 1991;48:548–55.
   Google Scholar
• Irle E, Exner C, Thielen K, Weniger G, Ruther E. Obsessive- compulsive disorder and ventromedial frontal lesions: clinical and neuropsychological findings. Am J Psychiatry 1998;155:255–63.
   PubMedGoogle Scholar
• Baer L, Rauch SL, Ballantine HT, Martuza R, Cosgrove R, Cassem E, et al. Cingulotomy for intractable obsessive- compulsive disorder: prospective long-term follow-up of 18 pa- tients. Arch Gen Psychiatry 1995;52:384–92.
   PubMed Web of Science ®Google Scholar
• Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake in- hibitors (SSRIs). Psychopharmacol Bull 1996;32:167–73.
   PubMed Web of Science ®Google Scholar
• Foa EB, Kozak MJ. Psychological treatment for obsessive- compulsive disorder. In: Mavissakalian MR, Prien RF, eds. Long-term treatments of anxiety disorders. Washington, DC: American Psychiatric Press, 1996:285–309.
   Google Scholar